GenSight Biologics S.A. (EPA: SIGHT)
France
· Delayed Price · Currency is EUR 0.270
-0.018 (-6.09%)
Dec 19, 2024, 4:19 PM CET
GenSight Biologics Revenue
GenSight Biologics had revenue of 1.73M EUR in the half year ending June 30, 2024, a decrease of -59.35%. This brings the company's revenue in the last twelve months to 1.98M, down -40.66% year-over-year. In the year 2023, GenSight Biologics had annual revenue of 2.96M, down -39.08%.
Revenue (ttm)
1.98M
Revenue Growth
-40.66%
P/S Ratio
9.36
Revenue / Employee
179.64K
Employees
16
Market Cap
31.96M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 2.96M | -1.90M | -39.08% |
| Dec 31, 2022 | 4.87M | -2.84M | -36.89% |
| Dec 31, 2021 | 7.71M | 269.00K | 3.62% |
| Dec 31, 2020 | 7.44M | 2.53M | 51.53% |
| Dec 31, 2019 | 4.91M | 564.00K | 12.98% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sanofi | 48.45B |
| EssilorLuxottica Société anonyme | 25.83B |
| Sartorius Stedim Biotech S.A. | 2.74B |
| bioMérieux S.A. | 3.81B |
| Eurofins Scientific SE | 6.72B |
| Ipsen S.A. | 3.44B |
| Virbac SA | 1.34B |
| Ramsay Générale de Santé SA | 5.01B |
GenSight Biologics News
- 3 days ago - GenSight Biologics Provides Update on Regulatory Discussions and Financial Situation - Business Wire
- 5 weeks ago - GenSight Biologics Announces Submission of LUMEVOQ® Dossier to ANSM to Prepare for Restart of Early Access Program in France - Business Wire
- 7 weeks ago - GenSight Biologics Announces Publication of Meta-Analyses Showing Better Outcomes for ND4-LHON Patients Treated with LUMEVOQ® - Business Wire
- 2 months ago - GenSight Biologics Reports Cash Position as of September 30, 2024, and Provides Business Update - Business Wire
- 2 months ago - GenSight Biologics Announces LUMEVOQ® Scientific Updates at AAO 2024 - Business Wire
- 3 months ago - GenSight Biologics S.A. reports 1H results - Seeking Alpha
- 3 months ago - GenSight Biologics Reports Interim Financial Results for the First Half of 2024, Provides Business Updates - Business Wire
- 5 months ago - GenSight Biologics Reports Cash Position as of June 30, 2024, and Provides Business Update - Business Wire